JO3546B1 - طريقة لإنتاج مشتق ثيازول - Google Patents

طريقة لإنتاج مشتق ثيازول

Info

Publication number
JO3546B1
JO3546B1 JOP/2016/0004A JOP20160004A JO3546B1 JO 3546 B1 JO3546 B1 JO 3546B1 JO P20160004 A JOP20160004 A JO P20160004A JO 3546 B1 JO3546 B1 JO 3546B1
Authority
JO
Jordan
Prior art keywords
span
sup
dir
ltr
formula
Prior art date
Application number
JOP/2016/0004A
Other languages
English (en)
Inventor
Yanagisawa Arata
Chujo Iwao
Tada Atsushi
Sugita Takamasa
Taga Masashi
Mimura Akihiro
Aoki Masashi
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Application granted granted Critical
Publication of JO3546B1 publication Critical patent/JO3546B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

يتعلق الاختراع بطريقة لإنتاج مشتق ثيازول يتم تمثيله بواسطة الصيغة(<span dir="LTR">I</span>)، له عمل مضاد لمستقبل أدينوزين <span dir="LTR">A<sub>2A</sub></span> ويعد مفيدًا باعتباره عاملاً علاجيًا لـ، على سبيل المثال، داء باركنسون، اضطرابات النوم، المقاومة المسكنة للمواد الأفيونية، الصداع النصفي، اضطراب الحركة، الاكتئاب، اضطراب القلق وما شابه. كما يتم أيضًا توفير طريقة إنتاج لمركب يتم تمثيلة بواسطة الصيغة(ج)، التي تحتوي على (1) خطوة إحداث تفاعل مركب يتم تمثيله بواسطة الصيغة(أ) ومركب يتم تمثيله بواسطة الصيغة(ب)، وما شابه: (ج) (ب) (أ) <span dir="LTR"><img src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></span> (حيث تمثل <span dir="LTR">R<sup>1</sup></span> الفوريل، تكون <span dir="LTR">R<sup>4</sup></span> و <span dir="LTR">R<sup>4</sup></span> و <span dir="LTR">R<sup>6</sup></span> نفسها أو مختلفة وتميل كل واحدة منها ألكيل أو أريل أدنى، تمثل <span dir="LTR">R<sup>2</sup> </span> بيريديل أو تيترا هيدرو بيرانيل، وتمثل <span dir="LTR">X<sup>1</sup></span> هالوجين).
JOP/2016/0004A 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول JO3546B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015002964 2015-01-09

Publications (1)

Publication Number Publication Date
JO3546B1 true JO3546B1 (ar) 2020-07-05

Family

ID=56356063

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2016/0004A JO3546B1 (ar) 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول
JOP/2020/0093A JOP20200093A1 (ar) 2015-01-09 2020-05-03 طريقة لإنتاج مشتق ثيازول

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2020/0093A JOP20200093A1 (ar) 2015-01-09 2020-05-03 طريقة لإنتاج مشتق ثيازول

Country Status (24)

Country Link
US (3) US10214523B2 (ar)
EP (2) EP3242877B1 (ar)
JP (2) JP6770962B2 (ar)
CN (1) CN107108602B (ar)
AR (1) AR103380A1 (ar)
AU (1) AU2016205657B2 (ar)
BR (1) BR112017014179A2 (ar)
CA (2) CA2972746C (ar)
CL (1) CL2017001695A1 (ar)
CO (1) CO2017006204A2 (ar)
DK (1) DK3242877T3 (ar)
ES (1) ES2861050T3 (ar)
HR (1) HRP20210385T1 (ar)
HU (1) HUE053567T2 (ar)
IL (2) IL252906B (ar)
JO (2) JO3546B1 (ar)
MX (2) MX379107B (ar)
PL (1) PL3242877T3 (ar)
PT (1) PT3242877T (ar)
RS (1) RS61570B1 (ar)
RU (2) RU2020141085A (ar)
SI (1) SI3242877T1 (ar)
TW (2) TWI729810B (ar)
WO (1) WO2016111381A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3546B1 (ar) * 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445350B (sv) * 1978-04-14 1986-06-16 Roussel Uclaf Oximderivat av 3-azidometyl-7-amino-tiazolyl-acetamido-cefalosporansyra och dess anvendning som antibiotika
TWI349550B (en) * 2003-12-26 2011-10-01 A thiazole derivative and adenosine a2a receptor antagonist containing the same
DE602005013793D1 (de) * 2004-07-27 2009-05-20 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
DK1921077T3 (en) 2005-08-02 2017-10-23 Kyowa Hakko Kirin Co Ltd Means for treating and / or preventing sleep disorders
KR101452518B1 (ko) 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
ZA200801857B (en) * 2005-08-31 2009-07-29 Astellas Pharma Inc Thiazole derivative
AU2006285834A1 (en) * 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
NZ590793A (en) 2008-07-23 2012-07-27 Kyowa Hakko Kirin Co Ltd Therapeutic agent for migraine
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6266270B2 (ja) 2013-05-20 2018-01-24 セイコーインスツル株式会社 運動フォーム解析装置および運動フォーム解析方法
JO3546B1 (ar) * 2015-01-09 2020-07-05 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول

Also Published As

Publication number Publication date
JOP20200093A1 (ar) 2020-05-03
EP3822269A1 (en) 2021-05-19
CA3080031A1 (en) 2016-07-14
CN107108602A (zh) 2017-08-29
TW201639835A (zh) 2016-11-16
TWI732748B (zh) 2021-07-11
IL252906A0 (en) 2017-08-31
TW202035397A (zh) 2020-10-01
EP3242877A1 (en) 2017-11-15
HUE053567T2 (hu) 2021-07-28
AR103380A1 (es) 2017-05-03
JP2018501282A (ja) 2018-01-18
EP3242877B1 (en) 2020-12-16
IL272811A (en) 2020-04-30
WO2016111381A1 (en) 2016-07-14
BR112017014179A2 (pt) 2018-03-06
HRP20210385T1 (hr) 2021-04-16
US20180002326A1 (en) 2018-01-04
PT3242877T (pt) 2021-03-11
JP6770962B2 (ja) 2020-10-21
DK3242877T3 (da) 2021-03-08
JP2020193209A (ja) 2020-12-03
US10894790B2 (en) 2021-01-19
EP3242877A4 (en) 2018-10-17
CA2972746A1 (en) 2016-07-14
PL3242877T3 (pl) 2021-05-31
US10214523B2 (en) 2019-02-26
RU2017128217A3 (ar) 2019-02-11
MX2017009008A (es) 2017-09-27
RU2017128217A (ru) 2019-02-11
CL2017001695A1 (es) 2018-03-23
CA2972746C (en) 2020-07-07
CN107108602B (zh) 2021-08-03
JP7068402B2 (ja) 2022-05-16
US20200216438A1 (en) 2020-07-09
TWI729810B (zh) 2021-06-01
MX2021000711A (es) 2021-03-25
US20190144438A1 (en) 2019-05-16
US10618894B2 (en) 2020-04-14
RU2020141085A (ru) 2021-02-10
RS61570B1 (sr) 2021-04-29
MX379107B (es) 2025-03-10
ES2861050T3 (es) 2021-10-05
IL252906B (en) 2020-03-31
RU2738937C2 (ru) 2020-12-18
CA3080031C (en) 2022-04-12
CO2017006204A2 (es) 2017-11-10
AU2016205657B2 (en) 2019-01-17
AU2016205657A1 (en) 2017-07-13
SI3242877T1 (sl) 2021-04-30

Similar Documents

Publication Publication Date Title
JO3648B1 (ar) عملية لتحضير (4s)- 4-(4- سيانو-2- ميثوكسي فينيل)-5-إيثوكسي-8،2- داي ميثيل-4،1- دايهيدرو-6،1- نفثيريدين-3- كربوكساميد وتنقيته للاستخدام كمقوم نشط دوائيا
JO3489B1 (ar) مركبات تراي أزولوبيريميدين واستخداماتها
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
EA201891742A1 (ru) Замещенное пиперидиновое соединение и его применение
EA201792355A1 (ru) Способ получения противоракового средства 1-((4-(4-фтор-2-метил-1h-индол-5-илокси)-6-метоксихинолин-7-илокси)метил)циклопропанамина, его кристаллической формы и солей
MA32975B1 (ar) مضادات c5ar
JOP20170100B1 (ar) توليف مركبات إندازول
PH12015501832B1 (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA200970583A1 (ru) Способ получения пиперазиниловых и диазепаниловых производных бензамида
CY1111477T1 (el) Θειενοπυριδινες ως αλλοστερικοι ενισχυτες του μ4 μουσκαρινικου υποδοχεα
JP2015532645A5 (ar)
NO20075086L (no) Behandling av Parkinsons sykdom, obstruktiv sovn apne, demens med Lewy legemer, vaskulaer demens med ikke-imidazol alkylamin histamin H3-reseptor ligander
TW201613884A (en) Selective NR2B antagonists
JOP20170101B1 (ar) توليف مركبات إندازول
CN110799501A (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
AR093787A1 (es) Derivados de aminociclobutano, su metodo de preparacion y su uso como medicamentos
SG10201900536TA (en) Piperidine derivatives as orexin receptor antagonist
JOP20200093A1 (ar) طريقة لإنتاج مشتق ثيازول
PE20161415A1 (es) Derivados de etinilo
MX388855B (es) Hidrogenacion catalitica de cianopiridinas sustituidas y proceso para la preparacion de piridilmetilbenzamidas sustituidas.
MX2020005241A (es) Proceso para la preparacion de fluopicolida.
MX2015000064A (es) Compuestos de acrilamida como ligandos receptores de histamina h3.